新辅助化疗治疗局部晚期非小细胞肺癌对CEA、CA-125、CYFRA21-1及淋巴细胞亚群产生的影响研究  

Effect of neoadjuvant chemotherapy on CEA,CA-125,CYFRA21-1 and lymphocyte subsets in locally advanced non-small cell lung cancer

作　　者：鞠英杰 JU Ying-jie(Oncology Department,Bengang Chest Hospital,Benxi 117000,China)

机构地区：[1]本钢胸科医院肿瘤科,117000

出　　处：《中国现代药物应用》2020年第22期23-25,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究新辅助化疗治疗局部晚期非小细胞肺癌对血清癌胚抗原(CEA)、糖类抗原125(CA-125)、细胞角蛋白19片段抗原(CYFRA21-1)及淋巴细胞亚群产生的影响。方法80例局部晚期非小细胞肺癌患者,依据治疗方法不同分为观察组和对照组,每组40例。观察组进行新辅助化疗治疗,对照组进行常规化疗治疗。对比两组患者治疗前后CEA、CA-125、CYFRA21-1及淋巴细胞亚群水平的变化情况。结果治疗后,两组患者血清CEA、CA-125、CYFRA21-1水平均较治疗前明显降低,且观察组CEA(19.28±4.32)ng/ml、CA-125(16.28±3.58)U/ml、CYFRA21-1(15.53±3.84)ng/ml明显低于对照组的(27.38±4.11)ng/ml、(21.32±3.46)U/ml、(21.39±3.22)ng/ml,差异有统计学意义(P<0.05)。治疗后,两组患者CD4^+、CD8^+、CD4^+/CD8^+水平均优于治疗前,且观察组CD8^+(31.93±3.59)%高于对照组的(28.58±3.52)%,CD4^+(21.43±4.34)%、CD4^+/CD8^+(0.67±0.12)低于对照组的(25.35±4.37)%、(0.89±0.17),差异有统计学意义(P<0.05)。结论新辅助化疗在非小细胞肺癌治疗中的应用,可显著降低肿瘤标志物指标水平,改善淋巴细胞亚群水平,临床应用效果显著。Objective To investigate the effect of neoadjuvant chemotherapy on carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA-125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and lymphocyte subsets in locally advanced non-small cell lung cancer.Methods A total of 80 patients with locally advanced non-small cell lung cancer were divided into observation group and control group according to different treatment methods,with 40 cases in each group.The observation group was treated with neoadjuvant chemotherapy,and the control group was treated with conventional chemotherapy.The levels of CEA,CA-125,CYFRA21-1 and lymphocyte subsets were compared between the two groups.Results After treatment,the levels of CEA,CA-125,CYFRA21-1 of the two groups were obviously lower than those before treatment,and CEA(19.28±4.32)ng/ml,CA-125(16.28±3.58)U/ml,CYFRA21-1(15.53±3.84)ng/ml of the observation group were obviously lower than(27.38±4.11)ng/ml,(21.32±3.46)U/ml,(21.39±3.22)ng/ml of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD4^+,CD8^+,CD4^+/CD8^+of the two groups were better than those before treatment;CD8^+(31.93±3.59)%of the observation group was higher than(28.58±3.52)%of the control group,and CD4^+(21.43±4.34)%,CD4^+/CD8^+(0.67±0.12)were lower than(25.35±4.37)%,(0.89±0.17)of the control group,and the difference was statistically significant(P<0.05).Conclusion Neoadjuvant chemotherapy has significant clinical application effect in the treatment of non-small cell lung cancer,which can significantly reduce the level of tumor markers and improve the level of lymphocyte subsets.

关 键 词：肺癌 非小细胞肺癌 新辅助化疗 多西他塞 

分 类 号：R734.2[医药卫生—肿瘤]